William Blair & Company
DFTX

William Blair & Company’s Definium Therapeutics DFTX Stock Holding History

William Blair & Company’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Sell
53,588
-107
-0.2% -$2.64K 0.01% 705
2026
Q1 		$1.01M Buy
+53,695
New +$911K ﹤0.01% 938
2025
Q4 		– Sell
-31,905
Closed -$376K – 1918
2025
Q3 		$376K Buy
31,905
+9,687
+44% +$90.3K ﹤0.01% 1215
2025
Q2 		$144K Buy
22,218
+9,718
+78% +$63.9K ﹤0.01% 1470
2025
Q1 		$73.1K Buy
+12,500
New +$89.5K ﹤0.01% 1543
2024
Q4 		– Sell
-11,000
Closed -$62.6K – 1858
2024
Q3 		$62.6K Sell
11,000
-268
-2% -$1.86K ﹤0.01% 1604
2024
Q2 		$81.2K Sell
11,268
-73
-0.6% -$638 ﹤0.01% 1537
2024
Q1 		$107K Buy
+11,341
New +$64.7K ﹤0.01% 1497
2021
Q4 		– Sell
-885
Closed -$32K – 2003
2021
Q3 		$32K Sell
885
-177
-17% -$7.65K ﹤0.01% 1726
2021
Q2 		$55K Buy
+1,062
New +$55.7K ﹤0.01% 1681

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

William Blair & Company's DFTX Position: Q2 2026 in Review

William Blair & Company reduced its Definium Therapeutics (DFTX) stake by 0.2% in Q2 2026, selling an estimated $2.64K and leaving 53,588 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #705.

William Blair & Company first reported a position in DFTX in Q2 2021 and has held it in 10 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • William Blair & Company held 53,588 shares of Definium Therapeutics worth $2.52M as of Q2 2026.
  • William Blair & Company sold 107 Definium Therapeutics shares in Q2 2026, an estimated $2.64K.
  • Definium Therapeutics made up 0.01% of William Blair & Company's portfolio in Q2 2026, its #705 holding.
  • William Blair & Company first reported a position in Definium Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.